HBM HOLDINGS-B (02142) Stock Price, News, Quotes-Moomoo

HK Stock MarketDetailed Quotes

02142 HBM HOLDINGS-B

Watchlist

1.180
-0.020-1.67%

Market Closed Nov 26 16:08 CST

902.48MMarket Cap5.44P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Heptagon Pharmaceuticals-B (02142.HK) spent HKD 0.2404 million to repurchase 0.2 million shares on November 25.
Gelonghui, November 25th丨Hepalink Pharmaceutical-B (02142.HK) announced that on November 25, 2024, it spent 0.2404 million HKD to repurchase 0.2 million shares, with a repurchase price of 1.19-1.21 HKD per share.
Gelonghui FinanceNov 25 04:22 ET
On November 22, Huabo Pharmaceuticals-B (02142.HK) spent 0.244 million Hong Kong dollars to repurchase 0.2 million shares.
On November 22, Gelonghui announced that Heber Pharmaceuticals-B (02142.HK) spent 0.244 million Hong Kong dollars to repurchase 0.2 million shares.
Gelonghui FinanceNov 22 06:02 ET
Express News | Harbour Biomed Appoints DR. Raymond Zheng as Chief Business Officer
ReutersNov 14 20:56 ET
Pharmaceutical announced the appointment of Dr. Zheng Lei as Chief Commercial Officer.
On November 15, 2024, in Suzhou, China, Cambridge, Massachusetts, usa, and Rotterdam, Netherlands / PRNewswire / - HuaBo Pharmaceutical (stock code: 02142.HK), a global biomedical company specializing in innovative antibody therapy discovery, development, and commercialization in the fields of oncology and immunology, today formally appointed Dr. Zheng Lei as Chief Business Officer (CBO). Dr. Zheng will be based in the usa and will be responsible for the company's global business expansion and asset management, reporting directly to Dr. Wang Jinsong, founder, chairman, and CEO of HuaBo Pharmaceutical. During his tenure as Chief Business Officer, Dr. Zheng will effectively
PR NewswireNov 14 20:55 ET
Press Release: Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
Dow JonesNov 14 20:55 ET
Bo Pharm (02142) has submitted a new drug clinical trial application for the treatment of chronic obstructive pulmonary disease to the National Medical Products Administration.
Jingu News | Hubei Pharmaceuticals (02142) announced that the Group has submitted an application for a new drug clinical trial (IND) of HBM9378 (or SKB378, as described by Sichuan Kellon Biomedical Pharmaceutical Co., Ltd. (06990) and the Group's development partner of HBM9378) to the National Medical Products Administration. The drug is a fully human antibody targeting thymic stromal lymphopoietin ("TSLP"), used to treat chronic obstructive pulmonary disease ("COPD").
Jingu financial newsNov 8 04:09 ET

Comments

Bamboo Works

Dec 22, 2023 01:06

Columns HBM gets health boost from drug licensing deals

HBM gets health boost from drug licensing deals
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...

Spinee

Dec 14, 2022 02:59

Vaccine Makers Shoot up as CN Unveils Implementation Plan for Covid Vaccine Booster Shots

Specifically, a second booster shot will be administered to people from high-risk groups, citizens older than 60, patients with chronic fundamental diseases and those with compromised immune systems.
Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up. $CANSINOBIO (06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million. $RECBIO-B (02179.HK)$ , $INNOCARE (09969.HK)$ and ...